Prostate cancer stem cells

Journal of Pathology

Volumn 217, Issue 2, 2009, Pages 299-306

  Lang, S H ^a   Frame, F M ^a   Collins, A T ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

Author keywords

Neoplasia; Prostate; Stem cells

Indexed keywords

ANTINEOPLASTIC AGENT; CHECKPOINT KINASE 1 INHIBITOR; CHECKPOINT KINASE 2 INHIBITOR; PROTEIN INHIBITOR; TUMOR MARKER; UNCLASSIFIED DRUG;

ANATOMY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER RISK; CANCER STEM CELL; CARCINOGENESIS; CELL TRANSFORMATION; DNA DAMAGE; DNA REPAIR; DOUBLE STRANDED DNA BREAK; EPITHELIUM CELL; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CARCINOMA; RADIOSENSITIVITY; REVIEW;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; MALE; MODELS, ANIMAL; NEOPLASTIC STEM CELLS; PROSTATE; PROSTATIC NEOPLASMS; STEM CELL NICHE; STEM CELLS;

EID: 58449089751     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2478     Document Type: Review

References (95)

1. Huggins C, Stevens RE Jr, Hodges CV. Studies on prostate cancer: the effects of castration on advanced carcinoma of the prostate gland. Arch Surg 1941;43:209-223.
2. Edwards J, Krishna NS, Grigor KM, Bardett JM. Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br J Cancer 2003;89:552-556.
3. Taplin ME, Rajeshkimar B, Halabi S, Werner CP, Woda BA, Picus J, et al. Androgen receptor mutations in androgen- independent prostate cancer. Cancer and Leukemia group B study, 9663. J Clin Oncol 2003;21:2673-2678.
4. Chen CD,Welsbie DS,Tran C,Baek SH, Chen R,Vessella R, et al. Molecular determinants of resistance to anti androgen therapy. Nat Med 2004;10:33-39.
5. Li P, Yu X, Ge K, Melamed J, Roeder RG, Wang Z. Heterogeneous expression and functions of androgen receptor co-factors in primary prostate cancer. Am J Pathol 2002;161:1467-1474.
6. Koivisto P, Kolmer M, Visakorpi T, Kallioniemi OP. Androgen receptor gene and hormonal therapy failure of prostate cancer. Am J Pathol 1998;152:1-9.
7. Roudier MP, True LD, Higano CS Vesselle H, Ellis W, Lange P, et al. Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Hum Pathol 2003;34:646-653.
8. Wernert N, Seitz G, Achtstätter T. Immunohistochemical investigation of different cytokeratins and vimentin in the prostate from the fetal period up to adulthood and in prostate carcinoma. Pathol Res Pract 1987;182:617-626.
9. Aumüller G, Groos S, Renneberg H, et al. Embryology and postnatal development of the prostate. In Pathology of the Prostate, Foster C, Bostwick D (eds). W. B. Saunders: New York, 1990; 1-17.
10. Sar M, Lubahn DB, French FS, Wilson EM. Immunohistochemi- cal localisation of the androgen receptor in rat and human tissues. Endocrinology 1990;127:3180-3186.
11. Kyprianou N, Isaacs JT. Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology 1988;122:552-562.
12. Bonkoff H, Remberger K. Widespread distribution of nuclear androgen receptors in the basal cell layer of the normal and hyperplastic human prostate. Virchows Arch Pathol Anat Histopathol 1993;422:35-38.
13. Aumüller G. Morphologic and endocrine aspects of prostatic function. Prostate 1983;4:195-214.
14. Bonkoff H, Stein U, Remberger K. Endocrine-paracrine cell types in the prostate and prostatic adenocarcinoma are postmitotic cells. Hum Pathol 1995;26:167-170.
15. English HF, Santen RJ, Isaacs JT. Response of glandular versus basal rat ventral prostate epithelial cells to androgen withdrawal and replacement. Prostate 1987;11:229-242.
16. Isaacs JT. Control of cell proliferation and cell death in the normal and neoplastic prostate: a stem cell model. In Benign Prostatic Hyperplasia, Rodgers CH, Coffey DS, Cunha G, Grayhack JT, Hinman F Jr, Horton R (eds). US Department of Health and Human Services: Rodgers CH, Coffey DS, Cunha G, Grayhack JT, Hinman F Jr, Horton R (eds). NIH Publication No. 87-2881. US Department of Health and Human Services: Washington, DC, 1987; 85-94.
17. Signoretti S, Waltregny D, Dilks J, Isaac B, Lin D, Garraway L, et al. p63 is a prostate basal cell marker and is required for prostate development. Am J Pathol 2000;157:1769-1775.
18. Signoretti S, Pires MM, Lindauer M, Horner JW, Grisanzio C, Dhar S, et al. p63 regulates commitment to the prostate cell lineage. Proc Natl Acad Sci USA 2005;102:11355-11360.
19. Kurita T, Medina RT, Mills AA, Cunha GR. Role of p63 and basal cells in the prostate. Development 2004;131:4955-4964.
20. Yang A, Schweitzer R, Sun D, Kaghad M, Walker N, Bronson RT. et al. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 1999;398:714-718.
21. Sugimura Y, Cunha GR, Donjacour AA. Morphogenesis of ductal networks in the mouse prostate. Biol Reprod 1986a;34:973-983.
22. Kinbara H, Cunha GR, Boutin E, Hayashi N, Kawamura J. Evidence of stem cells in the adult prostatic epithelium based upon responsiveness to mesenchymal inductors. Prostate1996;29:7-116.
23. Tsujimura A, Koikawa Y, Salm S, Takao T, Coetzee S, Moscatelli D, et al. Proximal location of mouse prostate epithelial stem cells: a model of prostatic homeostasis. JCellBiol 2002;157:1257-1265.
24. Salm SN, Burger PE, Coetzee S, Goto K, Moscatelli D, Wilson LE. TGF-ß maintains dormancy of prostatic stem cells in the proximal region of ducts. J Cell Biol 2005;170(1):81-90.
25. Xin L, Lawson DA, Witte ON. The Sca-1 cell surface marker enriches for a prostate-regenerating cell subpopulation that can initiate prostate tumorigenesis. Proc Natl Acad Sci USA 2005;102:6942-6947.
26. Collins AT, Habib FK, Maitland NJ, et al. Identification and isolation of human prostate epithelial stem cells based on α2β1- integrin expression. J Cell Sci 2001;114:3865-3872.
27. Hudson DL, O'Hare M, Watt FM, Masters JR Proliferative heterogeneity in the human prostate: evidence for epithelial stem cells. Lab Invest 2001;80:1243-1250.
28. Richardson GD, Robson CN, Lang SH, Neal DE, Maitland NJ, Collins AT. CD133, a novel marker for human prostatic epithelial stem cells. J Cell Sci 2004;117:3539-3545.
29. Mao P, Angrist A. The fine structure of the basal cell of human prostate. Lab Invest 1966;15:1768-1782.
30. Brandes D. The fine structure and histochemistry of pro-static glands in relation to sex hormones. Int Rev Cytol 1966;20:207-276.
31. Sherwood ER, Berg LA, Mitchell NJ, McNeal JE, Kozlowski JM, Lee C. Differential cytokeratin expression in normal hyperplastic and malignant epithelial cells from human prostate. J Urol 1990;143:167-171.
32. Verhagen AP, Ramaekers FCS, Aalders TW, Schaafsma HE, Debruyne FM, Schalken JA. Colocalization of basal and luminal cell-type cytokeratins in human prostate cancer. Cancer Res 1992;52:6182-6187.
33. Van Leenders G, Dijkman H, Hulsbergen-van de Kaa C, et al. Demonstration of intermediate cells during human prostate epithelial differentiation in situ and in vitro using triple-staining confocal scanning microscopy. Lab Invest 2000;80:1251-1258.
34. Yamashita YM, Jones DL, Fuller MT. Orientation of asymmetric stem cell division by the APC tumor suppressor and centrosome. Science 2003;301:1547-1550.
35. Yamashita YM, Mahowald AP, Perlin JR, Fuller MT. Asymmetric inheritance of mother versus daughter centrosome in stem cell division. Science 2007;315:518-521.
36. Tanentzapf G, Devenport D, Godt D, Brown NH. Integrin- dependent anchoring of a stem-cell niche. Nat Cell Biol 2007;9:1413-1418.
37. Taddei I, Deugnier MA, Faraldo MM, Petit V, Bouvard D, Medina D, et al. β1 integrin deletion from the basal compartment of the mammary epithelium affects stem cells. Nat Cell Biol 2008;10:716-722.
38. Cunha GR, Donjacour AA. Mesenchymal-epithelial interactions in the growth and development of the prostate. Cancer Treat Res 1989;46:159- 175.
39. Taylor RA, Cowin P, Cunha GR, Pera M, Trounson AO, Pedersen J, et al. Formation of human prostate tissue from embryonic stem cells. Nat Methods 2006;3:179-181.
40. Barclay WW, Axanova LS, Chen W, Romero L, Maund SL, Soker S, et al. Characterization of adult prostatic progenitor/stem cells exhibiting self-renewal and multilineage differentiation. Stem Cells 2008;26:600-610.
41. Lang SH, Stark M, Collins A, Paul AB, Stower MJ, Maitland NJ. Experimental prostate epithelial morphogenesis in response to stroma and three-dimensional Matrigel culture. Cell Growth Diff 2001;12:631- 640.
42. Kiger AA, Jones DL, Schulz C, Rogers MB, Fuller MT. Stem cell self-renewal specifed by JAK-STAT activation in response to a support cell cue. Science 2001;294:2542-2545.
43. Tulina N, Matunis E. Control of stem cell self-renewal in Drosophila spermatogenesis by JAK-STAT signalling. Science 2001;294:2546-2549.
44. Fuller M, Spradling AC. 2007;The male and female Drosophila germline stem cell niches: two versions of immortality. Science 316:402-404.
45. Li L, Xie T. Stem cell niche: structure and function. Annu Rev Cell Dev Biol 2005;21:605-631.
46. Wang XD, Leow CC, Zha J, Tang Z, Modrusan Z, Radtke F, et al. Notch signaling is required for normal prostatic epithelial cell proliferation and differentiation. Dev Biol 2006;290:66-80.
47. Morrison SJ, Kimble J. Asymmetric and symmetric stem-cell divisions in development and cancer. Nature 2006;441:1068-1074.
48. Birnie R, Bryce SD, Roome C, Dussupt V, Droop A, Lang SH, et al. Gene expression profiling of human prostate cancer stem cells reveals a pro-inflammatory phenotype and the importance of extracellular matrix interactions. Genome Biol 2008;9(5):R83.
49. Decotto E, Spradling A. The Drosophila ovarian and testis stem cell niches: similar somatic cells and signals. Dev Cell 2005;9:501-505.
50. Fodde R, Brabletz T. Wnt/ß-catenin signaling in cancer stemness and malignant behavior. Curr Opin Cell Biol 2007;19:150-158.
51. Chung LW, Chang SM, Bell C, Zhau HE, Ro JY, von Eschen-bach AC. Co-inoculation of tumorigenic rat prostate mesenchymal cells with non-tumorigenic epithelial cells results in the development of carcinosarcoma in syngeneic and athymic animals. Int J Cancer 1989;43:1179-1187.
52. Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res 1999;59:5002-5011.
53. Jaleel MA, Tsai AC, Sarkar S, Freedman PV, Rubin LP. Stromal cell-derived factor-1 (SDF-1) signalling regulates human placental trophoblast cell survival. Mol Hum Reprod 2004;10(12):901-909.
54. Kucia M, Jankowski K, Reca R, Wysoczynski M, Bandura L, Allendorf DJ, et al. CXCR4-SDF-1 signalling, locomotion, chemotaxis and adhesion. J Mol Histol 2004;35(3):233-245.
55. Sugiyama T, Kohara H, Noda M, Nagasawa T. Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signalling in bone marrow stromal cell niches. Immunity 2006;25:977-988.
56. Roland J, Murphy BJ, Ahr B, Robert-Hebmann V, Delauzun V, Nye KE, et al. Role of the intracellular domains of CXCR4 in SDF-1-mediated signalling. Blood 2003;101:399-406.
57. Eaves CJ. SDF-1 tells stem cells to mind their Ps and Zs. J Clin Invest 2005;115:27-29.
58. Nagle RB, Ahmann FR, McDaniel KM, Paquin ML, Clark VA, Celniker A. Cytokeratin characterisation of human prostatic carcinoma and its derived cell lines. Cancer Res 1987;47:281 -286.
59. kip1 in normal, hyperplastic, and neoplastic cells. Am J Pathol 1998;153:911 -919.
60. Van Leenders GJIH, Schalken JA. Stem cell differentiation within the human prostate epithelium: implications for prostate carcinogenesis. BJU Int 2001;21:35-42.
61. Liu AY, Nelson PS, van den Engh G, Hood L. Human prostate epithelial cell-type cDNA libraries and prostate expression patterns. Prostate 2002;50:92-103.
62. Craft N, Chhor C, Tran C, Belldegrun A, DeKernion J, Witte ON, et al. Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. Cancer Res 1999;59:5030-5036.
63. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005;65(23):10946-10951.
64. + prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 2006;25:1696-1708.
65. Gu G, Yuan J, Wills ML, Kasper S. Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo. Cancer Res 2007;67:4807-4815.
66. Nowell PC, Hungerford DA. Chromosome studies on normal and leukemic human leukocytes. J Natl Cancer Inst 1960;25:85-109.
67. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997;3:730-737.
68. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310:644-648.
69. Demichelis F, Rubin MA. TMPRSS2-ETS fusion prostate cancer; biological and clinical implications. J Clin Pathol 2007;60:1185- 1186.
70. Tomlins SA, Laxman B, Varambally S, Cao X, Yu J, Helgeson BE, et al. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 2008;10(2):177-188.
71. Cerveira NFR, Peixoto A, Costa V, Henrique R, Jeronimo C. TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions. Neoplasia 2006;8(10):826-832.
72. Mehra R, Tomlins SA, Yu J, Cao X, Wang L, Menon A, et al. Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. Cancer Res 2008;68(10):3584-3590.
73. Setlur SR, Mertz KD, Hoshida Y, Demichelis F, Lupien M, Perner S, et al. Estrogen-dependent signalling in a molecularly distinct subclass of aggressive prostate cancer. Cancer Res 2008;68(10):3584-3590.
74. Wang S, Gao J, Lei Q Rozengurt N, Pritchard C, Jiao J, et al. Prostate-specific deletion of the murine Pten tumour-suppressor gene leads to metastatic prostate cancer. Cancer Cell 2003; 4:209-221.
75. Wang S, Garcia AJ, Wu M, Lawson SA, Witte ON, Wu H. Pten deletion leads to the expansion of a prostatic stem/progenitor subpopulation and tumour initiation. Proc Natl Acad Sci USA 2006;103:1480-1485.
76. Xin L, Lawson DA, Witte ON. The Sca-1 cell surface marker enriches for a prostate-regenerating cell subpopulation that can initiate prostate tumourigenesis. Proc Natl Acad Sci USA 2005;102:6942-6947.
77. Xin L, Teitell MA, Lawson DA, Kwon A, Mellinghoff IK, Witte ON. Progression of prostate cancer by synergy of AKT with genotropic and nongenotropic actions of the androgen receptor. Proc Natl Acad Sci USA 2006;103:7789-7794.
78. Harrison DE, Lerner CP. Most primitive hematopoietic stem cells are stimulated to cycle rapidly after treatment with 5-fluorouracil. Blood 1991;78:1237-1240.
79. Chaudhary PM, Roninson IB. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 1991;66:85-94.
80. Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, Morris JJ, et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 2001;7:1028-1034.
81. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006;444(7120):756-760.
82. Chiou SH, Kao CL, Chen YW, Chien CS, Hung SC, Lo JF, et al. Identification of CD133-positive radioresistant cells in atypical teratoid/rhabdoid tumor. PLoS ONE 2008;3(5):e2090.
83. + HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene 2008;27(12):1749-1758.
84. Damia G, D'Incalci M. Targeting DNA repair as a promising approachin cancertherapy. EurJCancer2007;43(12):1791 -1801.
85. Ding J, Miao ZH, Meng LH, Geng MY. Emerging cancer therapeutic opportunities target DNA-repair systems Trends Pharmacol Sci 2006;27(6):338-344.
86. + cancer stem cells in glioblastoma. Mol Cancer 2006;5:67.
87. Murat A, Migliavacca E, Gorlia T, Lambiv WL, Shay T, Hamou M, et al. Stem cell-related 'self-renewal' signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol 2008;26(18):3015- 3024.
88. Hällström TM, Laiho M. Genetic changes and DNA damage responses in the prostate Prostate 2008;68(8):902-918.
89. Fan R, Kumaravel TS, Jalali F, Marrano P, Squire JA, Bristow RG. Defective DNA strand break repair after DNA damage in prostate cancer cells: implications for genetic instability and prostate cancer progression. Cancer Res 2004;64(23):8526-8533.
90. Fan C, Auan R, Feng X, Gillis A, He L, Matsumoto ED, et al. ATM activation is accompanied with earlier stages of prostate tumorigenesis. Biochim Biophys Acta 2006;1763(10):1090-1097.
91. Bartek J, Bartkova J, Lukas J. DNA damage signaling guards against activated oncogenes and tumour progression. Oncogene 2007;26(56): 7773-7779.
92. Yeh CC, Lee C, Dahiya R. DNA mismatch repair enzyme activity and gene expression in prostate cancer. Biochem Biophys Res Commun 2001;285(2):409-413.
93. Trzeciak AR, Nyaga SG, Jaruga P, Lohani A, Dizdaroglu M, Evans MK. Cellular repair of oxidatively induced base lesions is defective in prostate cancer cell lines PC-3 and Du145. Carcinogenesis 2004;25(8):1359- 1370.
94. Dong JY. Prevalent mutations in prostate cancer. J Cell Biochem 2006;97(3):443-447.
95. Bristow RG, Ozcelik H, Jalali F, Chan N, Vesprini D. Homologous recombination and prostate cancer: a model for novel DNA repair targets and therapies. Radiother Oncol 2007;83(3):220-230.